ResMed reports record results in latest quarter

ResMed has experienced a record-breaking financial performance in the latest financial quarter, during which it saw a year-on-year revenue increase of 12 percent.

During the three months ending on March 31st 2011, which represented the third quarter of ResMed's current fiscal year, the company's sales rose to a benchmark total of $313.3 million.

Europe and Asia Pacific were highlighted as particularly strong areas for growth, while positive performances were noted in the categories of flow generators and patient interface systems.

Dr Peter Farrell, chairman and chief executive officer of ResMed, stated that further growth in the rest of the year is expected to be driven by its expansion in the underserved sleep-disordered breathing market.

"There is evidence coming to light that early intervention in the treatment of sleep-disordered breathing may slow or prevent the progression of chronic diseases," he explained.

Last month, the company launched its new S9 VPAP bilevel device range, which allows for the comfortable treatment of a variety of respiratory conditions.